10
Nov

ArQule’s badly battered shares managed a quick surge this morning on news that the biotech’s lead drug tivantinib scored a positive outcome in a Phase II metastatic prostate cancer study.

…read more

Source: Battered ArQule shares bump up on badly needed positive data for tivantinib

    

0 No comments